A Prospective, Single-center, Open-arm, Single-arm Study of the Safety and Preliminary Efficacy of Single Intravenous Infusion Administration of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
Latest Information Update: 21 Feb 2025
At a glance
- Drugs LY-M001 (Primary)
- Indications Gaucher's disease type I
- Focus Adverse reactions
Most Recent Events
- 14 Feb 2025 Planned End Date changed from 17 Oct 2028 to 17 Dec 2031.
- 14 Feb 2025 Planned primary completion date changed from 17 Aug 2024 to 17 Dec 2026.
- 15 Dec 2023 New trial record